1. Homogeneous antibody and CAR-T cells with improved effector functions targeting SSEA-4 glycan on pancreatic cancer
- Author
-
Chih-Wei Lin, Yu-Jen Wang, Ting-Yen Lai, Tsui-Ling Hsu, Shin-Ying Han, Han-Chung Wu, Chia-Ning Shen, Van Dang, Ming-Wei Chen, Lan-Bo Chen, and Chi-Huey Wong
- Subjects
Stage-Specific Embryonic Antigens ,Multidisciplinary ,Cell- and Tissue-Based Therapy ,Mice, Nude ,Biological Sciences ,Immunotherapy, Adoptive ,Xenograft Model Antitumor Assays ,Antibodies ,Pancreatic Neoplasms ,Mice ,Gene Expression Regulation ,Cell Line, Tumor ,embryonic structures ,Animals ,Humans ,Immunotherapy - Abstract
Pancreatic cancer is usually asymptomatic in the early stages; the 5-y survival rate is around 9%; and there is a lack of effective treatment. Here we show that SSEA-4 is more expressed in all pancreatic cancer cell lines examined but not detectable in normal pancreatic cells; and high expression of SSEA-4 or the key enzymes B3GALT5 + ST3GAL2 associated with SSEA-4 biosynthesis significantly lowers the overall survival rate. To evaluate potential new treatments for pancreatic cancer, homogeneous antibodies with a well-defined Fc glycan for optimal effector functions and CAR-T cells with scFv construct designed to target SSEA-4 were shown highly effective against pancreatic cancer in vitro and in vivo. This was further supported by the finding that a subpopulation of natural killer (NK) cells isolated by the homogeneous antibody exhibited enhancement in cancer-cell killing activity compared to the unseparated NK cells. These results indicate that targeting SSEA-4 by homologous antibodies or CAR-T strategies can effectively inhibit cancer growth, suggesting SSEA-4 as a potential immunotherapy target for treating pancreatic disease.
- Published
- 2021